Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Wakix price?

See the DrugPatentWatch profile for Wakix

Wakix is a prescription medication used to treat narcolepsy with or without cataplexy, and also excessive daytime sleepiness (EDS) in adults with narcolepsy [1]. The price of Wakix can vary depending on several factors, including insurance coverage, pharmacy, and dosage [2].

How Much Does Wakix Cost Without Insurance?


Without insurance, the retail price for a 30-day supply of Wakix can be as high as $7,000 to $9,000 [2]. This significant cost can make it unaffordable for many individuals.

Can I Get Financial Assistance for Wakix?


Yes, there are options for financial assistance that can help reduce the out-of-pocket cost of Wakix.

What is the Wakix Savings Program?


The Wakix Savings Program, offered by the manufacturer (Sumitomo Pharma), can significantly lower the cost for eligible commercially insured patients. This program allows patients to pay as little as $10 for a 30-day supply, with a maximum savings of $150 per prescription and a maximum annual benefit of $1,800. Eligibility requirements apply, and the program is not available to those with government-sponsored insurance [3].

Are There Other Patient Assistance Programs?


For uninsured patients or those with government insurance who do not qualify for the savings program, there are other avenues for potential assistance. The manufacturer may offer patient assistance programs (PAPs) that provide free or low-cost medication to eligible individuals based on income and other criteria. Exploring these options is crucial for managing the cost of treatment [2].

How Does Insurance Affect Wakix Pricing?


Insurance coverage plays a critical role in determining the final price of Wakix for patients.

What Insurance Plans Cover Wakix?


Many private insurance plans cover Wakix. However, the amount a patient pays will depend on their specific plan's formulary, deductible, copay, and coinsurance. It is recommended to check with your insurance provider or a pharmacist to understand your coverage details [1, 2].

What if My Insurance Doesn't Cover Wakix?


If your insurance plan does not cover Wakix, or if the cost is still prohibitive, exploring the manufacturer's savings programs or patient assistance programs becomes even more important. In some cases, a healthcare provider may be able to assist in appealing insurance denials or seeking alternative treatment options if Wakix is not covered [2].

What is the Dosage and How Does it Impact Price?


Wakix is available in different strengths, and the dosage prescribed will influence the total cost. The typical starting dose for adults is 20 mg once daily, which can be increased to 40 mg once daily. Higher doses will naturally lead to higher overall treatment costs, making the impact of savings programs more significant [1, 2].

When Does Wakix Patent Expiry Occur?


Information regarding the specific patent expiry dates for Wakix is often detailed and can be subject to extensions or challenges. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity periods, which can provide insights into when generic versions might become available, potentially impacting future pricing [4].

What Are the Alternatives to Wakix?


For individuals with narcolepsy or EDS, there are other treatment options available besides Wakix. These may include stimulant medications, wakefulness-promoting agents, or sodium oxybate. The choice of treatment often depends on individual symptom severity, medical history, and response to different therapies [1].

Sources:
[1] Wakix Official Website
[2] GoodRx
[3] Sumitomo Pharma - Wakix Savings Program
[4] DrugPatentWatch.com



Other Questions About Wakix :

Wakix generic entries? Wakix product withdrawn uk? How many more years does wakix have on their patten? Wakix price us? Wakix and litigation? Wakix generic name? Wakix drug price annual?

AI-Drug Label Prescribing Information Alignment Report

18
18%
Grade D

Poor

Mostly Unaligned

Patient Risk: Moderate

Summary

The response includes mostly non-label marketing/program and pricing statements that are not supported by the provided FDA label excerpts. The dosing statements (starting dose and max dose) conflict with the label excerpts for adult dosing range and do not match the provided titration framework. Only the general indication for EDS/cataplexy in narcolepsy is supported.


Category Scores

Indication
90
Excellent
Dosage
10
Poor

Accurate Statements

Wakix is a prescription medication used to treat narcolepsy with or without cataplexy.
Section 1 INDICATIONS AND USAGE: indicated for treatment of EDS or cataplexy in patients 6 years of age and older with narcolepsy.
Wakix is used to treat excessive daytime sleepiness (EDS) in adults with narcolepsy.
Section 1 INDICATIONS AND USAGE: indicated for treatment of EDS or cataplexy in patients 6 years of age and older with narcolepsy (includes adults).

Unsupported Statements

The price of Wakix can vary depending on insurance coverage, pharmacy, and dosage.
No pricing/insurance/program information appears in the provided FDA label excerpts.
Without insurance, the retail price for a 30-day supply of Wakix can be as high as $7,000 to $9,000.
No pricing information appears in the provided FDA label excerpts.
The Wakix Savings Program is offered by the manufacturer (Sumitomo Pharma).
No patient savings program or manufacturer-sponsored program details appear in the provided FDA label excerpts.
The Wakix Savings Program can lower the cost for eligible commercially insured patients.
No patient savings/eligibility/cost-lowering program details appear in the provided FDA label excerpts.
The Wakix Savings Program allows patients to pay as little as $10 for a 30-day supply.
No dollar-amount program details appear in the provided FDA label excerpts.
The Wakix Savings Program has a maximum savings of $150 per prescription.
No dollar-amount program details appear in the provided FDA label excerpts.
The Wakix Savings Program has a maximum annual benefit of $1,800.
No dollar-amount program details appear in the provided FDA label excerpts.
Eligibility requirements apply for the Wakix Savings Program.
No patient savings program eligibility details appear in the provided FDA label excerpts.
The Wakix Savings Program is not available to those with government-sponsored insurance.
No patient savings program availability/insurance-type restrictions appear in the provided FDA label excerpts.
The manufacturer may offer patient assistance programs (PAPs) that provide free or low-cost medication to eligible individuals based on income and other criteria.
No PAP details appear in the provided FDA label excerpts.
Many private insurance plans cover Wakix.
No payer coverage statements appear in the provided FDA label excerpts.
A patient's cost for Wakix depends on their plan's formulary, deductible, copay, and coinsurance.
No cost/share statements appear in the provided FDA label excerpts.
Wakix is available in different strengths.
The label excerpt supports multiple strengths (4.45 mg and 17.8 mg tablets) but the statement is generic; it is not incorrect. It is not directly tied to a specific label strength list beyond the excerpt provided.
Higher doses of Wakix will naturally lead to higher overall treatment costs.
No cost relationship/dose-cost statement appears in the provided FDA label excerpts.

Contradictions

Low

AI Statement
The typical starting dose for adults is 20 mg once daily.

Label Reference
Section 2.2 Recommended Dosage in Adult Patients: recommended dosage range for adults is 17.8 mg to 35.6 mg once daily in the morning upon wakening (no '20 mg once daily' starting dose stated).

Low

AI Statement
The adult dose of Wakix can be increased to 40 mg once daily.

Label Reference
Section 2.2 Recommended Dosage in Adult Patients: recommended dosage range for adults is 17.8 mg to 35.6 mg once daily (no 40 mg once daily maximum stated).


Important Omissions

Provided label dosage information for adults includes a recommended range (17.8 mg–35.6 mg once daily) and titration over weeks, plus missed-dose guidance and the possibility of up to 8 weeks to achieve response; the response instead states specific 'typical' start/increase doses that conflict with label excerpts.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Conflicting adult dosing claims (20 mg starting; increase to 40 mg) are not supported by the provided adult dosage range in the label excerpt (17.8 mg–35.6 mg). Other statements are largely unrelated to clinical safety because they concern pricing/programs not addressed in the provided label excerpts.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Unaligned

Primary Issue
Adult dosing statements ('typical starting dose 20 mg once daily' and 'increase to 40 mg once daily') conflict with the provided FDA label excerpt showing an adult recommended dosage range of 17.8 mg to 35.6 mg once daily.

Suggested Improvement
Replace the adult starting/increase dose claims with the label-supported adult dosage range (17.8 mg–35.6 mg once daily) and avoid including specific pricing/savings/PAP dollar-amount and eligibility statements not present in the provided FDA label excerpts.

Drug Brand Mention Assessment

Branding Score
40
Visibility
45
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
conditional
Brand Perception
Best Known For

used to treat narcolepsy with or without cataplexy


Core Claims
  • Wakix is a prescription medication used to treat narcolepsy with or without cataplexy
  • Wakix can also treat excessive daytime sleepiness (EDS) in adults with narcolepsy
  • The price of Wakix can vary depending on insurance coverage, pharmacy, and dosage
  • Without insurance, the retail price for a 30-day supply can be as high as $7,000 to $9,000
  • There is a Wakix Savings Program that can lower cost for eligible commercially insured patients
Differentiators
  • Savings Program can lower cost to pay as little as $10 for a 30-day supply
  • Savings Program eligibility excludes government-sponsored insurance
  • Higher doses will lead to higher overall treatment costs

Pricing Perception: Premium
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
GoodRx 33%
50 #2 No
Sumitomo Pharma 25%
50 #3 No
DrugPatentWatch 25%
50 #4 No